University Duisburg-Essen-dr Bernd Giebel
University Duisburg-Essen
University of Duisburg-Essen belongs with 43 thousands of students from 130 countries to ten biggest universities in Germany. The academic institution focuses mainly on biomedical an nanotechnology research.
The University Hospital Essen (Universitaetsklinikum Essen) has focused on three major areas of research and treatment: cardiovascular diseases, transplant
ation medicine, genetic medicine, immunology and infectious diseases and mainly oncology. Therefore the Hospital has been designated as an Tumor Center of Western Germany (Westdeutsches Tumorzentrum, WTZ), which is one of the biggest centers of this type in Germany and has been acknowledged as a Leading Oncoloy Center (Onkologisches Spitzenzentrum) by the German Cancer Aid (Deutsche Krebshilfe) in 2013. The German Cancer Aid is supporting the research at WTZ with funds of 3 Mio euro for 3 years. Furthermore, the WTZ is a partner institution for the German Consortium for Cancer Translational Research (Deutsches Konsortiums für Translationale Krebsforschung - DKTK) - as the only institution from North Rhine-Westphalia and one of 7 in whole Germany. WTZ represents at the same time the Comprehensive Cancer Center for the Hospital Essen and has been combining and excellent patient care with oncology research of international range for 40 years. The University and Hospital conducts wide-ranging international collaborations with universities and research institutes from all over the world.
Dr Bernd Giebel
Research interest
- early human hematopoiesis
- regulation mechanisms of self-renewal and differentiation of hematopoietic stem cells
- therapeutic applications of MSC-derived small EVs
- optimization and standardization of large-scale production of MSC-EVs for clinical use
- imaging flow cytometry for small EV analysis
Dr Bernd Giebel is working in the Institute for Transusion Medicine (Institut für Transfusionsmedizin),which conducts, besides clinical activities, scientific research in the field of stem cells biology, transplantology and tumor immunology.
Via the identification of two asymmetrically segregating proteins in dividing human hematopoietic stem and progenitor cells, the tetraspanins CD53 and CD63, he became interested in extracellular vesicles (EVs). From 2009, his group started to work on purification and analysis methods for EVs, setting a focus on mesenchymal stem/stromal cell-derived EVs (MSC-EVs). Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. Within their project, which is part of a consortium funded by the EFRE.NRW program of the European Union and the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (SEVRIT - Produktion und Qualitätssicherung von Stammzell-abgeleiteten extrazellulären Vesikeln für neuartige regenerative und immunmodulierende Therapieansätze), they are optimizing and validating the large scale production of MSC-EVs in a clinical grade compatible manner.
Dr Giebel’s research group was a member of the ME-HAD COST Action (European Network on Microvesicles and Exosomes in Health and Disease under the European Cooperation in Science and Technology; https://www.cost.eu/actions/BM1202/#tabs|Name:overview) and led the working group Diagnostic & Therapeutic Potential of Microvesicles and Exosomes (ME). Since 2012 he is an active member of the International Society of Extracellular Vesicles (ISEV) and coordinated an ISEV position paper regarding the therapeutic application of EVs. Furthermore, he is the president of the German Society of Extracellular Vesicles (GSEV), which he founded together with other German EV experts in 2017. According to his expertise, he became part of the scientific advisory board of two SME companies, Innovex Therapeutics and EVOX. More recently dr Giebel got involved in the International Society of Gene and Cell Therapy (ISCT) now heading an exosome working group intending to promote translation of MSC-EVs into the clinics.
Dr Giebel has a broad and experience in the purification, characterization and analysis of the therapeutic activity of EVs and has published several articles on this topic. Due to the overall increasing interest in EV biology, the group is involved in several projects on the campus and is actively cooperating with different German and international groups.
Biography
Dr Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. 1999 he moved to the Heinrich-Heine-University of Düsseldorf, where he started to work with human hematopoietic stem and progenitor cells and set up his own group focusing on mechanisms controlling the decision of self-renewal versus differentiation of human somatic stem cells.. In 2008 he moved to the Institute of Transfusion Medicine at the University Hospital Essen. Here, he continues his studies on human somatic stem cells.
Publications (last 10 years)
1. Welsh JA, Van Der Pol E, Arkesteijn GJA, Bremer M, Brisson A, Coumans F, Dignat-George F, Duggan E, Ghiran I, Giebel B, et al.: MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J Extracell Vesicles 2020, 9:1713526.
2. Kordelas L, Gorgens A, Radtke S, Horn PA, Beelen DW, Giebel B: Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows. Bone Marrow Transplant 2020, 55:100-109.
3. Kontopoulou E, Strachan S, Reinhardt K, Kunz F, Walter C, Walkenfort B, Jastrow H, Hasenberg M, Giebel B, von Neuhoff N, et al.: Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics. Ann Hematol 2020, 99:459-475.
4. Dampmann M, Gorgens A, Mollmann M, Murke F, Duhrsen U, Giebel B, Durig J: CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo. PLoS One 2020, 15:e0228674.
5. Abel F, Murke F, Gaida M, Garnier N, Ochsenfarth C, Theiss C, Thielmann M, Kleinbongard P, Giebel B, Peters J, et al.: Extracellular vesicles isolated from patients undergoing remote ischemic preconditioning decrease hypoxia-evoked apoptosis of cardiomyoblasts after isoflurane but not propofol exposure. PLoS One 2020, 15:e0228948.
6. Witwer KW, Van Balkom BWM, Bruno S, Choo A, Dominici M, Gimona M, Hill AF, De Kleijn D, Koh M, Lai RC, et al.: Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles 2019, 8:1609206.
7. van Balkom BWM, Gremmels H, Giebel B, Lim SK: Proteomic Signature of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles. Proteomics 2019, 19:e1800163.
8. Sody S, Uddin M, Gruneboom A, Gorgens A, Giebel B, Gunzer M, Brandau S: Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions. Front Immunol 2019, 10:1419.
9. Ricklefs FL, Maire CL, Reimer R, Duhrsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, et al.: Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. J Extracell Vesicles 2019, 8:1588555.
10. Radtke S, Gorgens A, da Conceicao Castro SV, Kordelas L, Koninger A, Durig J, Mollmann M, Horn PA, Giebel B: Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice. Sci Rep 2019, 9:12914.
11. Kordelas L, Schwich E, Dittrich R, Horn PA, Beelen DW, Borger V, Giebel B, Rebmann V: Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness. Int J Mol Sci 2019, 20.
12. Kopp M, Aufderhorst UW, Alt M, Dittmer U, Eis-Hubinger AM, Giebel B, Roggendorf M, Epple M, Krawczyk A: Induction of herpes simplex virus type 1 cell-to-cell spread inhibiting antibodies by a calcium phosphate nanoparticle-based vaccine. Nanomedicine 2019, 16:138-148.
13. Gussenhoven R, Klein L, Ophelders D, Habets DHJ, Giebel B, Kramer BW, Schurgers LJ, Reutelingsperger CPM, Wolfs T: Annexin A1 as Neuroprotective Determinant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-Ischemic Encephalopathy. J Clin Med 2019, 8.
14. Gorgens A, Bremer M, Ferrer-Tur R, Murke F, Tertel T, Horn PA, Thalmann S, Welsh JA, Probst C, Guerin C, et al.: Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using fluorescence-tagged vesicles as biological reference material. J Extracell Vesicles 2019, 8:1587567.
15. Giebel B, Hermann DM: Identification of the right cell sources for the production of therapeutically active extracellular vesicles in ischemic stroke. Ann Transl Med 2019, 7:188.
16. Frey UH, Klaassen M, Ochsenfarth C, Murke F, Thielmann M, Kottenberg E, Kleinbongard P, Klenke S, Engler A, Heusch G, et al.: Remote ischaemic preconditioning increases serum extracellular vesicle concentrations with altered micro-RNA signature in CABG patients. Acta Anaesthesiol Scand 2019, 63:483-492.
17. Wiklander OPB, Bostancioglu RB, Welsh JA, Zickler AM, Murke F, Corso G, Felldin U, Hagey DW, Evertsson B, Liang XM, et al.: Systematic Methodological Evaluation of a Multiplex Bead-Based Flow Cytometry Assay for Detection of Extracellular Vesicle Surface Signatures. Front Immunol 2018, 9:1326.
18. Thivakaran A, Botezatu L, Hones JM, Schutte J, Vassen L, Al-Matary YS, Patnana P, Zeller A, Heuser M, Thol F, et al.: Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. Haematologica 2018, 103:614-625.
19. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al.: Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018, 7:1535750.
20. Ludwig AK, De Miroschedji K, Doeppner TR, Borger V, Ruesing J, Rebmann V, Durst S, Jansen S, Bremer M, Behrmann E, et al.: Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales. J Extracell Vesicles 2018, 7:1528109.
21. Hummel EM, Hessas E, Muller S, Beiter T, Fisch M, Eibl A, Wolf OT, Giebel B, Platen P, Kumsta R, et al.: Cell-free DNA release under psychosocial and physical stress conditions. Transl Psychiatry 2018, 8:236.
22. Doeppner TR, Bahr M, Giebel B, Hermann DM: Immunological and non-immunological effects of stem cell-derived extracellular vesicles on the ischaemic brain. Ther Adv Neurol Disord 2018, 11:1756286418789326.
23. Reiner AT, Witwer KW, van Balkom BWM, de Beer J, Brodie C, Corteling RL, Gabrielsson S, Gimona M, Ibrahim AG, de Kleijn D, et al.: Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles. Stem Cells Transl Med 2017, 6:1730-1739.
24. Hones JM, Thivakaran A, Botezatu L, Patnana P, Castro S, Al-Matary YS, Schutte J, Fischer KBI, Vassen L, Gorgens A, et al.: Enforced GFI1 expression impedes human and murine leukemic cell growth. Sci Rep 2017, 7:15720.
25. Giebel B, Kordelas L, Borger V: Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Investig 2017, 4:84.
26. Giebel B, Helmbrecht C: Methods to Analyze EVs. Methods Mol Biol 2017, 1545:1-20.
27. Giebel B: On the function and heterogeneity of extracellular vesicles. Ann Transl Med 2017, 5:150.
28. Drommelschmidt K, Serdar M, Bendix I, Herz J, Bertling F, Prager S, Keller M, Ludwig AK, Duhan V, Radtke S, et al.: Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. Brain Behav Immun 2017, 60:220-232.
29. Doeppner TR, Bahr M, Hermann DM, Giebel B: Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke. Stem Cells Transl Med 2017, 6:2044-2052.
30. Corso G, Mager I, Lee Y, Gorgens A, Bultema J, Giebel B, Wood MJA, Nordin JZ, Andaloussi SE: Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography. Sci Rep 2017, 7:11561.
31. Consortium E-T, Van Deun J, Mestdagh P, Agostinis P, Akay O, Anand S, Anckaert J, Martinez ZA, Baetens T, Beghein E, et al.: EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods 2017, 14:228-232.
32. Borger V, Bremer M, Ferrer-Tur R, Gockeln L, Stambouli O, Becic A, Giebel B: Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents. Int J Mol Sci 2017, 18.
33. Bauer D, Alt M, Dirks M, Buch A, Heilingloh CS, Dittmer U, Giebel B, Gorgens A, Palapys V, Kasper M, et al.: A Therapeutic Antiviral Antibody Inhibits the Anterograde Directed Neuron-to-Cell Spread of Herpes Simplex Virus and Protects against Ocular Disease. Front Microbiol 2017, 8:2115.
34. Zeuner MT, Patel K, Denecke B, Giebel B, Widera D: Paracrine effects of TLR4-polarised mesenchymal stromal cells are mediated by extracellular vesicles. J Transl Med 2016, 14:34.
35. Radtke S, Gorgens A, Liu B, Horn PA, Giebel B: Human mesenchymal and murine stromal cells support human lympho-myeloid progenitor expansion but not maintenance of multipotent haematopoietic stem and progenitor cells. Cell Cycle 2016, 15:540-545.
36. Ophelders DR, Wolfs TG, Jellema RK, Zwanenburg A, Andriessen P, Delhaas T, Ludwig AK, Radtke S, Peters V, Janssen L, et al.: Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl Med 2016, 5:754-763.
37. Nel I, Gauler TC, Bublitz K, Lazaridis L, Goergens A, Giebel B, Schuler M, Hoffmann AC: Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS One 2016, 11:e0153018.
38. Nardi Fda S, Konig L, Wagner B, Giebel B, Santos Manvailer LF, Rebmann V: Soluble monomers, dimers and HLA-G-expressing extracellular vesicles: the three dimensions of structural complexity to use HLA-G as a clinical biomarker. HLA 2016, 88:77-86.
39. Konig L, Kasimir-Bauer S, Hoffmann O, Bittner AK, Wagner B, Manvailer LF, Schramm S, Bankfalvi A, Giebel B, Kimmig R, et al.: The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. Hum Immunol 2016, 77:791-799.
40. Hones JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schutte J, Al-Matary YS, et al.: GFI1 as a novel prognostic and therapeutic factor for AML/MDS. Leukemia 2016, 30:1237-1245.
41. Hombach AA, Gorgens A, Chmielewski M, Murke F, Kimpel J, Giebel B, Abken H: Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack. Mol Ther 2016, 24:1423-1434.
42. Gorgens A, Murke F, Kordelas L, Giebel B: Lost in Transplantation? Unexpected shift from multipotent to late lymphomyeloid hematopoietic stem and progenitor cells in patients 1 year after hematopoietic stem cell transplantation. Bone Marrow Transplant 2016, 51:1073-1075.
43. Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, et al.: Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano 2016, 10:3886-3899.
44. Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hones JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, et al.: Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Exp Hematol 2016, 44:713-726 e714.
45. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, et al.: Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015, 4:27066.
46. Radtke S, Gorgens A, Kordelas L, Schmidt M, Kimmig KR, Koninger A, Horn PA, Giebel B: CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants. Br J Haematol 2015, 169:868-878.
47. Loffek S, Ullrich N, Gorgens A, Murke F, Eilebrecht M, Menne C, Giebel B, Schadendorf D, Singer BB, Helfrich I: CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol 2015, 5:234.
48. Lener T, Gimona M, Aigner L, Borger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, et al.: Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles 2015, 4:30087.
49. Krawczyk A, Dirks M, Kasper M, Buch A, Dittmer U, Giebel B, Wildschutz L, Busch M, Goergens A, Schneweis KE, et al.: Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody. PLoS One 2015, 10:e0116800.
50. Graffmann N, Brands J, Gorgens A, Vitoriano da Conceicao Castro S, Santourlidis S, Reckert A, Michele I, Ritz-Timme S, Fischer JC, Adjaye J, et al.: Age-Related Increase of EED Expression in Early Hematopoietic Progenitor Cells is Associated with Global Increase of the Histone Modification H3K27me3. Stem Cells Dev 2015, 24:2018-2031.
51. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, Radtke S, de Miroschedji K, Horn PA, Giebel B, Hermann DM: Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med 2015, 4:1131-1143.
52. Denecke B, Horsch LD, Radtke S, Fischer JC, Horn PA, Giebel B: Human endothelial colony-forming cells expanded with an improved protocol are a useful endothelial cell source for scaffold-based tissue engineering. J Tissue Eng Regen Med 2015, 9:E84-97.
53. Malyar NM, Radtke S, Malyar K, Arjumand J, Horn PA, Kroger K, Freisinger E, Reinecke H, Giebel B, Brock FE: Autologous bone marrow mononuclear cell therapy improves symptoms in patients with end-stage peripheral arterial disease and reduces inflammation-associated parameters. Cytotherapy 2014, 16:1270-1279.
54. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Epple M, Horn PA, Beelen DW, Giebel B: MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28:970-973.
55. Hemeda H, Giebel B, Wagner W: Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy 2014, 16:170-180.
56. Gorgens A, Ludwig AK, Mollmann M, Krawczyk A, Durig J, Hanenberg H, Horn PA, Giebel B: Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages. Stem Cell Reports 2014, 3:1058-1072.
57. Brandau S, Jakob M, Bruderek K, Bootz F, Giebel B, Radtke S, Mauel K, Jager M, Flohe SB, Lang S: Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One 2014, 9:e106903.
58. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Gorgens A, Giebel B, Schadendorf D, Paschen A: Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013, 133:1653-1663.
59. Muturi HT, Dreesen JD, Nilewski E, Jastrow H, Giebel B, Ergun S, Singer BB: Tumor and endothelial cell-derived microvesicles carry distinct CEACAMs and influence T-cell behavior. PLoS One 2013, 8:e74654.
60. Krawczyk A, Arndt MA, Grosse-Hovest L, Weichert W, Giebel B, Dittmer U, Hengel H, Jager D, Schneweis KE, Eis-Hubinger AM, et al.: Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A 2013, 110:6760-6765.
61. Gorgens A, Radtke S, Mollmann M, Cross M, Durig J, Horn PA, Giebel B: Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages. Cell Rep 2013, 3:1539-1552.
62. Gorgens A, Radtke S, Horn PA, Giebel B: New relationships of human hematopoietic lineages facilitate detection of multipotent hematopoietic stem and progenitor cells. Cell Cycle 2013, 12:3478-3482.
63. Ludwig AK, Giebel B: Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol 2012, 44:11-15.
64. Gorgens A, Beckmann J, Ludwig AK, Mollmann M, Durig J, Horn PA, Rajendran L, Giebel B: Lipid raft redistribution and morphological cell polarization are separable processes providing a basis for hematopoietic stem and progenitor cell migration. Int J Biochem Cell Biol 2012, 44:1121-1132.
65. Giebel B, Wodarz A: Notch signaling: numb makes the difference. Curr Biol 2012, 22:R133-135.
66. Doeppner TR, Ewert TA, Tonges L, Herz J, Zechariah A, ElAli A, Ludwig AK, Giebel B, Nagel F, Dietz GP, et al.: Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation. Stem Cells 2012, 30:1297-1310.
67. Sokolova V, Ludwig AK, Hornung S, Rotan O, Horn PA, Epple M, Giebel B: Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces 2011, 87:146-150.
68. Radtke S, Gorgens A, Punzel M, Horn P, Giebel B: Establishment of an extended in vitro assay to detect the most primitive human hematopoietic cells at a clonal level. J Stem Cells Regen Med 2010, 6:48.
69. Ludwig AK, Horn P, Giebel B: Characterisation of the endosomal machinery in human hematopoietic stem and progenitor cells. J Stem Cells Regen Med 2010, 6:86.
70. Jansen S, von Levetzow G, Goergens A, Hanenberg H, Horn P, Giebel B: Analysis of transcription factors differentially expressed in the primitive human hematopoietic compartment. J Stem Cells Regen Med 2010, 6:103.
71. Horsch L, Denecke B, Fischer J, Giebel B, Horn P: Evaluation of basal membrane-derived and biomaterial matrices for endothelial cell expansion and maintenance of their primitive potential. J Stem Cells Regen Med 2010, 6:104.
72. Goergens A, Beckmann J, Rajendran L, Horn PA, Giebel B: Functional analyses of cell polarity organization in human hematopoietic stem and progenitor cells. J Stem Cells Regen Med 2010, 6:74.